MiNK Therapeutics, Inc. announced on February 20, 2025, that it received formal notice from Nasdaq confirming its regained compliance with listing requirements. The company is now compliant with both the minimum bid price and market value of listed securities rules.
This compliance follows a previous notice from Nasdaq on May 13, 2025, indicating non-compliance with the Minimum Value of Listed Securities rule, as its market value had been below the $35 million threshold for the preceding 30 consecutive trading days. The company had until November 10, 2025, to regain compliance.
Regaining compliance is a significant step for MiNK Therapeutics, ensuring its continued listing on the Nasdaq exchange. This removes a potential delisting risk and maintains the company's access to public capital markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.